BIIB Stock Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Biogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$222.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | -0.038 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | 0.91% |
| 5 Year Change | -4.31% |
| Change since IPO | -27.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIIB | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 15.5% | 2.6% |
| 1Y | 0% | 51.7% | 8.8% |
Return vs Industry: BIIB underperformed the Swiss Biotechs industry which returned 51.7% over the past year.
Return vs Market: BIIB underperformed the Swiss Market which returned 8.8% over the past year.
Price Volatility
| BIIB volatility | |
|---|---|
| BIIB Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: BIIB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIIB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 7,570 | Chris Viehbacher | www.biogen.com |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
Biogen Inc. Fundamentals Summary
| BIIB fundamental statistics | |
|---|---|
| Market cap | CHF 25.57b |
| Earnings (TTM) | CHF 989.66m |
| Revenue (TTM) | CHF 8.26b |
25.8x
P/E Ratio3.1x
P/S RatioIs BIIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIIB income statement (TTM) | |
|---|---|
| Revenue | US$9.67b |
| Cost of Revenue | US$2.23b |
| Gross Profit | US$7.44b |
| Other Expenses | US$6.28b |
| Earnings | US$1.16b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.95 |
| Gross Margin | 76.92% |
| Net Profit Margin | 11.98% |
| Debt/Equity Ratio | 39.6% |
How did BIIB perform over the long term?
See historical performance and comparison